SELECT MEDICAL HOLDINGS CORP

Company Overview

Select Medical is a national post-acute healthcare operator focused on three complementary businesses: critical illness recovery hospitals (LTCHs), inpatient rehabilitation hospitals (IRFs) and outpatient rehabilitation clinics. As of year-end 2024 the company operated 104 LTCHs, 35 rehabilitation hospitals and ~1,914 outpatient clinics across 40 states and DC, generating $5.19 billion of revenue in 2024 with ~47% from LTCHs, ~21% from rehab hospitals and ~24% from outpatient services. Key operational levers are patient days, revenue per patient day/visit, lengths of stay (LTCH ~31 days; rehab ~14 days), payor mix (Medicare ~29% consolidated, higher in rehab), centralized clinical programs and scale-driven cost control, while reimbursement/regulatory shifts and labor shortages are principal near‑term risks.

Executive Compensation Practices

Compensation is likely tied to both financial and clinical performance given Select’s mix of specialized clinical programs and centralized cost structure: common pay metrics are adjusted EBITDA, revenue per patient day/visit, patient days/occupancy, free cash flow/deleveraging (post‑Concentra IPO leverage ~3.18x), and segment profitability (LTCH vs. rehab vs. outpatient). The 10‑K/MDA notes accelerated stock‑based compensation in 2024 and a meaningful equity/event (Concentra IPO and distribution) that materially changed capital structure, so long‑term equity (RSUs/options) and event‑driven vesting have been significant drivers — and management highlighted share repurchases as a capital allocation lever in 2025. Given the heavy regulatory exposure, compensation programs often incorporate non‑financial gates (quality/accreditation, compliance, audit outcomes, patient safety metrics) and are subject to clawback or forfeit provisions tied to fraud/abuse or certification failures.

Insider Trading Considerations

Material corporate events (Concentra IPO/distribution, large debt refinancings/prepayments, and share repurchase authorizations/actual repurchases) create obvious windows for insider transactions and historically have affected liquidity and insider selling/buying dynamics. Watch for insider selling around equity vesting and spin‑off distributions and for insider buying during or after announced repurchase activity; H1 2025 saw ~$96.5M in repurchases under a $1.0B authorization. Due to sensitivity to Medicare/Medicaid rule changes, audit outcomes and certification/licensure risks, insiders will have material nonpublic information tied to reimbursement guidance, RAC or outlier reconciliations and cybersecurity or compliance events — these circumstances trigger blackout periods, Rule 10b5‑1 plan use, and heightened regulatory scrutiny under Anti‑Kickback/Stark/HIPAA statutes.